107-43-7C[N+](C)(C)CC(=O)[O-]KWIUHFFTVRNATP-UHFFFAOYSA-NGlycine betaine is the amino acid betaine derived from glycine. It has a role as a fundamental metabolite. It is an amino-acid betaine and a glycine derivative. It is a conjugate base of a N,N,N-trimethylglycinium.
107-43-7Cosmetic ingredients (Betaine) -> CIR (Cosmetic Ingredient Review)
Antistatic; Viscosity controlling
Soluble
Solubility (g/100 g solvent): methanol, 55; ethanol, 8.7. Sparingly soluble in ether.
Slightly soluble in chloroform
In water, 6.11X10+5 mg/L at 19 °C
Very soluble
Soluble (in ethanol)
FDA approved drugs -> Active ingredient
EMA approved medicines: Human medicine
EMA approved medicines: Human medicine
FDA approved drugs -> Active ingredient
안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.
This chemical does not meet GHS hazard criteria for 90.4% (274 of 303) of all reports.
Not Classified
Aggregated GHS information provided per 303 reports by companies from 5 notifications to the ECHA C&L Inventory.
Chemical: Methanaminium, 1-carboxy-N,N,N-trimethyl-, hydroxide, innersalt
Regulation (EC) No 2015/2283 Article 10
Methanaminium, 1-carboxy-N,N,N-trimethyl-, inner salt is listed on the EPA's Chemical Data Reporting (CDR) system. Manufacturers and importers of Methanaminium, 1-carboxy-N,N,N-trimethyl-, inner salt are required to report information about their production and use of this chemical to the EPA under the Toxic Substances Control Act (TSCA). (40 eCFR Part 711)
REACH registered substance: Betaine (EC: 203-490-6)
Trimethylglycine: Does not have an individual approval but may be used under an appropriate group standard
No evidence of mutagenicity; [HSDB] Does not cross the placenta well in animal experiments; [REPROTOX] Not irritating to skin or eyes of rabbits; Not sensitizing in guinea pig maximization test; No evidence of mutagenicity; [IUCLID] May cause irritation; [Alfa Aesar MSDS]
The Approved Drug Products with Therapeutic Equivalence Evaluations List identifies currently marketed prescription drug products, incl betaine hydrochloride, approved on the basis of safety and effectiveness by FDA under sections 505 of the Federal Food, Drug, and Cosmetic Act. /Betaine hydrochloride/
Drug products containing certain active ingredients offered over-the-counter (OTC) for certain uses. A number of active ingredients have been present in OTC drug products for various uses, as described below. However, based on evidence currently available, there are inadequate data to establish general recognition of the safety and effectiveness of these ingredients for the specified uses: betaine hydrochloride is included in digestive aid drug products. /Betaine hydrochloride/
A - Alimentary tract and metabolism
QA - Alimentary tract and metabolism
Betaine decreases plasma homocysteine concentrations in homocystinuria cases caused by deficiencies or defects in cystathionine beta-synthase (CBS), 5,10-methylenetetrahydrofolate reductase (MTHFR), and cobalamin cofactor metabolism (cbl). The decrease of homocysteine is estimated to be 20-30% of pre-treatment levels. Betaine supplementation in patients with homocystinuria also improves metabolic abnormalities in cerebrospinal fluid. Reports have shown that depending on the type of homocystinuria, the therapeutic effectiveness of betaine alone may be limited, insufficient to decrease total homocysteine levels and prevent clinical symptoms. In patients with homocystinuria due to cystathionine beta-synthase (CBS) deficiency, betaine should be used when serum total homocysteine levels remain high despite dietary therapy. Patients taking betaine for several years do not show evidence of tolerance. Also, betaine concentrations are not correlated with homocysteine concentrations. In patients with MTHFR deficiency and cbl defects, betaine may increase methionine and S-adenosyl methionine (SAM) plasma levels. Patients with CBS deficiency without a dietary restriction of methionine may accumulate excessive amounts of methionine. Clinical data shows that in patients with CBS deficiency, increased plasma methionine levels were associated with cerebral edema.
Homocystinuria is a hereditary disorder characterized by high levels of the amino acid homocysteine. This condition can be caused by deficiencies or defects in cystathionine beta-synthase (CBS), 5,10-methylenetetrahydrofolate reductase (MTHFR), and cobalamin cofactor metabolism (cbl). CBS converts homocysteine to cystathionine, and a deficiency in this enzyme can lead to an accumulation of homocysteine. MTHFR is responsible for producing 5-methyltetrahydrofolate, a methyl donor that participates in the conversion of homocysteine back to methionine; therefore, an MTHFR deficiency can also lead to homocystinuria. Additionally, a defect in cobalamin (vitamin B12) cofactor metabolism can lead to homocystinuria, since a metabolite of cobalamin (methylcobalamin) promotes the conversion of homocysteine to methionine. Betaine transfers a methyl group via the enzyme betaine homocysteine methyl transferase (BHMT), converting homocysteine back into methionine and dimethylglycine (DMG). In patients with homocystinuria, betaine reduces homocysteine levels and improves health outcomes.
현재 필터 조건에 해당하는 반응 기록이 없습니다.
불러오는 중…
DTXSID8022666CHEMBL1182、CHEMBL95889CHEBI:17750301-305°C
Decomposes around 293 °C
Liquid; Dry Powder
Deliquescent solid; [Merck Index] Powder; [Alfa Aesar MSDS]
Free-flowing, white crystals; Savoury
SRP: At the time of review, criteria for land treatment or burial (sanitary landfill) disposal practices are subject to significant revision. Prior to implementing land disposal of waste residue (including waste sludge), consult with environmental regulatory agencies for guidance on acceptable disposal practices.
The aim of this study was to assess the pharmacokinetics of orally administered betaine and its acute effect on plasma total homocysteine (tHcy) concentrations. Healthy volunteers (n = 10; 3 men, 7 women) with normal body weight (mean + or - SD, 69.5 + or - 17.0 kg), 40.8 + or - 12.4 yr old, participated in the study. The betaine doses were 1, 3, and 6 g. The doses were mixed with 150 mL of orange juice and ingested after a 12-hr overnight fast by each volunteer according to a randomized double-blind crossover design. Blood samples were drawn for 24 hr and a 24-hr urine collection was performed. Orally administered betaine had an immediate and dose-dependent effect on serum betaine concentration. Single doses of 3 and 6 g lowered plasma tHcy concentrations (P = 0.019 and P < 0.001, respectively), unlike the 1-g dose. After the highest dose, the concentrations remained low during the 24 hr of monitoring. The change in plasma tHcy concentration was linearly associated with betaine dose (P = 0.006) and serum betaine concentration (R2 = 0.17, P = 0.025). The absorption and elimination of betaine were dose dependent. The urinary excretion of betaine seemed to increase with an increasing betaine dose, although a very small proportion of ingested betaine was excreted via urine. In conclusion, a single dose of orally administered betaine had an acute and dose-dependent effect on serum betaine concentration and resulted in lowered plasma tHcy concentrations within 2 hr in healthy subjects.
The prophylactic efficiency of taurine or betaine pretreatment for the prevention of peroxidative changes induced by lipopolysaccharide treatment in the rat liver was investigated ... Lipopolysaccharide (10 mg/kg intraperitoneally) was given to rats pretreated with taurine (1.5%, w/v) or betaine (1.5%, w/v) in drinking water for 4 weeks and plasma transaminase activities as well as hepatic malondialdehyde, diene conjugate (DC), glutathione, alpha-tocopherol and ascorbic acid levels, and superoxide dismutase (SOD) and glutathione peroxidase activities were determined ... Significant increases in plasma transaminase activities and hepatic malondialdehyde and DC levels and decreases in hepatic glutathione and alpha-tocopherol levels and SOD and glutathione peroxidase activities were observed 6 h after lipopolysaccharide treatment. This treatment did not alter ascorbic acid levels in the liver compared with controls. Taurine or betaine pretreatment in lipopolysaccharide-injected rats caused significant decreases in plasma transaminase activities and hepatic malondialdehyde and DC levels, and significant increases in glutathione and alpha-tocopherol (not betaine) levels without changing ascorbic acid levels and SOD and glutathione peroxidase activities in the liver ... /According to the authors/ taurine or betaine pretreatment was effective in the prevention of lipopolysaccharide-induced hepatotoxicity and prooxidant status.
Concomitant use of betaine and folic acid may be additive with regard to the possible lowering of serum homocysteine levels.
... Remethylation of homocysteine to methionine can occur through either the folate-dependent methionine synthase pathway or the betaine-dependent betaine-homocysteine methyltransferase pathway. The relevance of betaine as a determinant of fasting total homocysteine (tHcy) is not known, nor is it known how the 2 remethylation pathways are interrelated ... The objectives of the study were to examine the relation between plasma betaine concentration and fasting plasma tHcy concentrations and to assess the effect of folic acid supplementation on betaine concentrations in healthy subjects ... A double-blind randomized trial of 6 incremental daily doses of folic acid (50-800 ug/day) or placebo was carried out in 308 Dutch men and postmenopausal women (aged 50 to 75 yr). Fasted blood concentrations of tHcy, betaine, choline, dimethylglycine, and folate were measured at baseline and after 12 wk of vitamin supplementation ... Concentrations of tHcy were inversely related to the betaine concentration (r = -0.17, P < 0.01), and the association was independent of age, sex, and serum concentrations of folate, creatinine, and cobalamin. Folic acid supplementation increased betaine concentration in a dose-dependent manner (P for trend = 0.018); the maximum increase (15%) was obtained at daily doses of 400 to 800 ug/day ... /The authors condluded/ the plasma betaine concentration is a significant determinant of fasting tHcy concentrations in healthy humans. Folic acid supplementation increases the betaine concentration, which indicates that the 2 remethylation pathways are interrelated.
In small, open label trials of betaine therapy for homocystinuria as well as in small controlled trials of betaine in other conditions (Alzheimer disease, nonalcoholic steatohepatitis), serum enzyme elevations and clinically apparent liver injury were not reported. Indeed, in some studies, betaine has been associated with significant declines in preexisting serum enzyme elevations in a proportion of patients with nonalcoholic fatty liver disease.
TERRESTRIAL FATE: Based on a classification scheme(1), an estimated Koc value of 3(SRC), determined from a water solubility of 611,000 mg/L at 19.3 °C(2) and a regression-derived equation(3), indicates that betaine is expected to have very high mobility in soil(SRC). The estimated pKa of betaine, an inner salt, is 2.38(4). Volatilization of betaine from moist soil surfaces is not expected to be an important fate process(SRC) because ionic compounds do not volatilize. Betaine is not expected to volatilize from dry soil surfaces(SRC) based upon an estimated vapor pressure of 1.4X10-8 mm Hg(SRC), determined from a fragment constant method(5). No information on the aerobic biodegradation of betaine was located; however, the mineralization of alkyl betaine surfactants is considerable (>60% BODT reached in 28-day screening tests(6,7)) indicating that it is likely that betaine is also readily mineralized(SRC). Betaine is expected to biodegrade under anaerobic conditions as well based on data indicating that it is removed during anaerobic sewage treatment(8).
AQUATIC FATE: Based on a classification scheme(1), an estimated Koc value of 3(SRC), determined from a water solubility of 611,000 mg/L at 19.3 °C(2) and a regression-derived equation(3), indicates that betaine is not expected to adsorb to suspended solids and sediment(SRC). An estimated pKa of 2.38(4) indicates betaine, will exist entirely as an inner salt at pH values of 5 to 9 and therefore volatilization from water surfaces will not occur as ionic compounds do not volatilize. According to a classification scheme(5), an estimated BCF of 0.3(SRC), from its water solubility(2) and a regression-derived equation(6), suggests the potential for bioconcentration in aquatic organisms is low(SRC). No information on the aerobic biodegradation of betaine was located; however, the mineralization of alkyl betaine surfactants is considerable (>60% BODT reached in 28-day screening tests(7,8)) indicating that it is likely that betaine is also readily mineralized(SRC). Betaine is expected to biodegrade under anaerobic conditions as well based on data indicating that it is removed during anaerobic sewage treatment(9).
ATMOSPHERIC FATE: According to a model of gas/particle partitioning of semivolatile organic compounds in the atmosphere(1), betaine, which has an estimated vapor pressure of 1.4X10-8 mm Hg at 25 °C(SRC), determined from a fragment constant method(2), is expected to exist solely in the particulate phase in the ambient atmosphere. Particulate-phase betaine may be removed from the air by wet or dry deposition(SRC). Betaine does not contain chromophores that absorb at wavelengths >290 nm and therefore is not expected to be susceptible to direct photolysis by sunlight(3).
The betaine concentration of over 400 foods in the U.S. was measured. Concentrations ranged from 0.3 to 1.9 mg/100 g food for 26 dairy and egg products, 0.4 to 28.8 mg/100 g food for 16 spices, 0 to 1.8 mg/100 g food for 7 samples of fats and oils, 1.8 to 23.3 mg/100 g food for 16 samples of chicken and turkey, 2.1 to 10.4 mg/100 g for 18 sausage and luncheon meats, 0.5 to 1396.1 mg/100 g for 15 samples of breakfast cereals, 0.1 to 0.8 mg/100 g for 35 fruits, 0.2 to 4.2 mg/100 g food for 10 pork product samples, 0.1 to 808.6 mg/100 g food for 62 vegetable products with beets and spinach containing significantly more betaine than other vegetables, 0.3 to 11.2 mg/100 g food for 12 nut and seed products, 6.3 to 12.8 mg/100 g food for 15 beef products, 0.1 to 8.1 mg/100 g food for 12 beverages, 2.1 to 62.1 mg/100 g food for 11 finfish and shellfish products, 0.1 to 39.6 mg/100 g food for 21 legumes and legume products, 7.6 to 33.9 mg/100 g food for 4 lamb, veal and game samples, 0.4 to 244.1 mg/100 g food for 43 baked products, 0.1 to 6.1 mg/100 g food for 20 sugars and sweets products, 0.3 to 1506.8 for 13 samples of cereal grains and pasta products, 0.5 to 98.2 mg/100 g for 50 samples of fast foods, 0.1 to 21.6 mg/100 g for 10 snacks (pretzels were 295.1 mg/100 g food)(1).
The CIR Expert Panel concluded that the eleven alkyl betaines listed below are safe in the present practices of use and concentration in cosmetics, when formulated to be non-irritating...Betaine...
Safe for use in cosmetics, with qualifications
The Koc of betaine is estimated as 3(SRC), using a water solubility of 611,000 mg/L at 19.3 °C(1) and a regression-derived equation(2). According to a classification scheme(3), this estimated Koc value suggests that betaine is expected to have very high mobility in soil. The estimated pKa of betaine, an inner salt, is 2.38(4).
AEROBIC: No data on the aerobic biodegradation of betaine was located however, amphoteric surfactants based on the betaine structure have been shown to be mineralized to a significant extent. For example, C12-C14 alkyl betaine surfactants were shown to be readily biodegradable in 28-day closed bottle screening tests reaching >60% of the theoretical oxygen demand over this period(1,2).
ANAEROBIC: Betaine was nearly completely degraded in two full-scale anaerobic treatment plants(1).
Drug Induced Liver Injury Rank (DILIrank 2.0)
Betaine
vNo-DILI-concern
0
No match
DOI:10.1016/j.drudis.2016.02.015
The Approved Drug Products with Therapeutic Equivalence Evaluations List identifies currently marketed prescription drug products, incl betaine hydrochloride, approved on the basis of safety and effectiveness by FDA under sections 505 of the Federal Food, Drug, and Cosmetic Act. /Betaine hydrochloride/
Drug products containing certain active ingredients offered over-the-counter (OTC) for certain uses. A number of active ingredients have been present in OTC drug products for various uses, as described below. However, based on evidence currently available, there are inadequate data to establish general recognition of the safety and effectiveness of these ingredients for the specified uses: betaine hydrochloride is included in digestive aid drug products. /Betaine hydrochloride/
Betaine acts as metabolic intermediate in transmethylating processes (creatine and methionine synthesis).
Betaine acts as a methyl group donor in the remethylation of homocysteine to methionine in patients with homocystinuria. This reduces toxic concentrations of homocysteine, usually to 20 to 30% or less of pretreatment concentrations.
Betaine or trimethylglycine is a quarternary ammonium compound that was first discovered in the juice of sugar beets (Beta vulgaris). Betaine is a metabolite of choline ... and is a substrate in one of the two recycling pathways that convert homocysteine to L-methionine. The other and principal recycling reaction is catalyzed by the enzyme methionine synthase and uses methylcobalamin as a cofactor and 5-methyltetrahydrofolate as a cosubstrate.
Betaine-homocysteine methyltransferase (BHMT) is a zinc metalloenzyme which catalyzes the transfer of a methyl group from betaine to homocysteine in the formation of methionine. BHMT is found in the liver and kidneys and may also exist in brain tissue. Betaine acts to lower homocysteine levels in some with primary hyperhomocysteinemia/homocystinuria via this enzyme.
In healthy volunteers (n=12) given 50 mg/kg of betaine, the elimination half-life was 14.38 h. In volunteers given 100 mg/kg/day of betaine for 5 days, the distribution half-life was significantly longer, suggesting that the transport and redistribution processes of betaine were saturated.
Betaine is catabolized mainly in the mitochondria of liver and kidney cells. The transmethylation of betaine via betaine homocysteine methyl transferase (BHMT) leads to the formation of dimethylglycine.
Betaine is absorbed from the small intestines into the enterocytes. It is released by the enterocytes into the portal circulation which carries it to the liver where there is significant first-pass extraction and first-pass metabolism of betaine. The principal metabolic reaction is the transfer of a methyl group from betaine to homocysteine via the enzyme betaine-homocysteine methyltransferase. The products of the reaction are L-methionine and dimethylglycine. Betaine hydrochloride is converted to betaine in the alkaline environment of the small intestine.
/Betaine/ is a metabolite of choline ...
3SCV180C9W
BETAINE
Mechanisms of Action [MoA] - Methylating Activity
Established Pharmacologic Class [EPC] - Methylating Agent
Betaine is a Methylating Agent. The mechanism of action of betaine is as a Methylating Activity.
BETAINE
Drugs used for their effects on the gastrointestinal system, as to control gastric acidity, regulate gastrointestinal motility and water flow, and improve digestion.
Endogenous factors or drugs that increase the transport and metabolism of LIPIDS including the synthesis of LIPOPROTEINS by the LIVER and their uptake by extrahepatic tissues.
Betaine is rapidly absorbed and distributed. In healthy volunteers (n=12) given 50 mg/kg of betaine, the Cmax, tmax and AUC0,∞ were 0.939 mmol/L, 0.90 h and 5.52 mmol⋅h/L, respectively. No significant changes in absorption kinetics were observed after repeated betaine administration (100 mg/kg/day for 5 days). The absolute bioavailability of betaine anhydrous has not been determined.
Betaine is mainly eliminated by metabolism. With a slow elimination rate and assuming 100% bioavailability, the renal clearance of betaine is negligible (5% of total body clearance).
Based on a study done on healthy volunteers (n=12) given 50 mg/kg of betaine, the volume of distribution was 1.3 L/kg.
Based on a study done on healthy volunteers (n=12) given 50 mg/kg of betaine, total oral plasma drug clearance was 0.084 L/h⋅kg.
Betaine is absorbed from the small intestines into the enterocytes. It is released by the enterocytes into the portal circulation which carries it to the liver where there is significant first-pass extraction and first-pass metabolism of betaine. The principal metabolic reaction is the transfer of a methyl group from betaine to homocysteine via the enzyme betaine-homocysteine methyltransferase. The products of the reaction are L-methionine and dimethylglycine. Betaine hydrochloride is converted to betaine in the alkaline environment of the small intestine.
It is not known whether betaine is distributed into breast milk. However, its metabolic precursor, choline, is found in human breast milk in high concentrations .
CIR ingredient: Betaine
Occurs naturally in plants and animals; Used in the treatment of homocystinuria; [Merck Index] Used in soldering and resin curing fluxes, in organic synthesis, and in fisheries (promotes fish survival and aids transfer of salmon and trout from freshwater to seawater); [HSDB]
Soldering [Category: Heat or Machine]
In soldering, resin curing fluxes, organic synthesis; in treatment of homocystinuria
Lipotropic drug
Gastric acidifier /Betaine hydrochloride/
Oral: For solution: 1 g/level scoopful Cystadane, (Orphan Medical)
Oral: 1 gram per 1.7 mL of powder (one scoopful) (Rx) (Cystadane).
Cystadane (betaine anhydrous for oral solution)
Betaine, in the form of a white, granular, hygroscopic powder referred to as anhydrous betaine ...
EPA Safer Chemical Functional Use Classes -> Processing Aids and Additives
Safer Chemical Classes -> Green half-circle - The chemical is expected to be of low concern
Flavoring Agents -> JECFA Flavorings Index
Flavouring Agent -> FLAVOURING_AGENT -> JECFA Functional Classes
Pharmaceuticals -> Animal Drugs -> Approved in Taiwan
Cosmetics -> Antistatic; Viscosity controlling
Printing Ink Manufacturing
Methanaminium, 1-carboxy-N,N,N-trimethyl-, inner salt: ACTIVE
개요무수 베타 인 작용 기작 : 인간에서는 베타 인 무수물 원료 인 API는 메틸기 기증자 및 보조 인자로서 다양한 역할을합니다. 특히 Betaine Anhydrous가 아미노산 호모시스테인 (homocysteine)의 아미노산 메틸화를 도와 줄 때 아미노산은 신체에서 적절히 조절되지 않으면 혈관 및 염증성 문제와 관련이 있습니다. 위의 이유로 베타 인 무수물은 많은 생물학적으로 중요한 분자와 호모 시스테인 수준 조절제의 배합에 필수적인 성분입니다. 또한, Betaine Anhydrous는 삼투압 물질입니다. 크레아틴과 마찬가지로 세포 수화를 촉진합니다. 무수 베타 인은 세포의 완전성과 정상적인 물의 균형을 유지하는데 기여합니다. 무수 베타 인은 불안 / 우울 조절에 이점이있는 것으로 보인다. 그 이유는 메티오닌 재생 과정에서 S- 아데 노일 메티오닌이 증가하기 때문입니다. S-adenoylmethionine은 다양한 연구에서 우울증과 불안증과 관련이 있습니다.
용도Betaine Hydrochloride (베타 인 Hcl)의 기능 : 1. 심장병 퇴치 또는 예방 2. 신체 조성을 개선하십시오. 간 해독과 우리 신체의 일부 세포 기능을 도와주세요. 3. 근육 강화 및 지방 손실을 촉진하십시오. Betaine Hydrochloride (Betaine Hcl)는 자연적으로 존재하는 화합물입니다. osmoregulation에있는 그것의 역할을 위해 관심사의 계속있다. 베타 인 하이드로 클로라이드 (Betaine Hcl)는 hypochlorhydria의 치료에서 염산의 공급원으로 사용되었습니다. Betaine은 또한 간 질환의 치료, 고칼륨 혈증, 호모 시스틴 뇨증 및 위장 장애에 사용되었습니다. Betaine Hydrochloride (Betaine Hcl)는 사탕무 및 기타 식물에서 발생하는 결정질 알칼로이드 인 베타 인의 염산염 형태입니다. Transethylating metabolic 중간체 역할을하는 Betaine 은 콜린 의 산화 생성물입니다. 베타 인 하이드로 클로라이드는 위산 산성 보충제로 사용됩니다. Betaine 은 여러 가지 대사 경로에서 메틸 기증자 역할을하는 3 개의 메틸기를 가진 글리신 으로 구성된 변형 된 아미노산이며 호모 시스틴뇨증의 드문 유전 적 원인을 치료하는 데 사용됩니다. 베타 인 은 임상 적 사용이 제한적 이었으나 치료 중 또는 임상 적으로 명백한 간 손상에 대한 혈청 효소 상승의 사례와 관련이 없었다.
개요Betaine is a natural compound extracted from Beta vulgaris, widely present in both leaves and roots. Within plants, betaine is synthesised through a two-step oxidation of choline within chloroplasts. The first step converts choline into betaine aldehyde, a rate-limiting step catalysed by choline monooxygenase. The second step converts betaine aldehyde to betaine, catalysed by betaine aldehyde dehydrogenase [1]. It possesses certain pharmacological activities and may be employed to treat deficiencies or defects in specific enzymes leading to hyperhomocysteinemia in blood and urine. This medication facilitates the removal of excess homocysteine from the body.[1] TAKABE T, TANAKA Y, TAKABE T. CHAPTER 2:Betaine in Sugar Beet[C]. 2015: 0. DOI:10.1039/9781782628446-00009.
용도betaine is a surfactant, humectant, and excellent skin conditioner. It is also used to build product viscosity and as a foam booster. It is found mostly in skin cleansers, shampoos, and bath products.
일반 설명Betaine also called trimethylglycine or N,N,N triethylammonium acetate, is an analog of glycine with three methyl groups. It is highly compatible with polymerase chain reaction (PCR) buffer mixture. Betaine is a PCR enhancing reagent that is widely used for improving the yield and specificity of PCR products, especially during the PCR amplification of targets rich in GC content or those that form secondary structures resulting in poor yield. Betaine facilitates DNA strand separation and manages the DNA melting temperature (Tm) difference between the GC and AT pairs in DNA. It stabilizes the ds DNA by equalizing the contribution of GC- and AT-base pairs. Betaine has been broadly used to optimize multiplex and ‘long and accurate′ polymerase chain reaction (LA-PCR). The addition of 1.0-1.7 M aqueous betaine to a PCR mixture has been reported to reduce the base pair composition dependence on DNA strand melting.
순도시험(1) 용상 : 이 품목 1g을 물 10mL에 녹일 때, 그 액은 무색 징명하여야 한다. (2) 액성 : 이 품목의 수용액(1→20)의 pH는 5.0~7.0이어야 한다. (3) 염화물 : 이 품목 1g을 취하여 염화물시험법에 따라 시험할 때, 그 양은 0.01N 염산 0.15mL에 대응하는 양 이하이어야 한다. (4) 황산염 : 이 품목 1g을 취하여 황산염시험법에 따라 시험할 때, 그 양은 0.01N 황산 0.2mL에 대응하는 양 이하이어야 한다. (5) 비소 : 이 품목을 비소시험법에 따라 시험할 때, 그 양은 4.0ppm 이하이어야 한다. (6) 납 : 이 품목 5.0g을 취하여 원자흡광광도법 또는 유도결합플라즈마발광광도법에 따라 시험할 때, 그 양은 2.0ppm 이하이어야 한다.
확인시험이 품목의 수용액(1→100)과 베타인표준품의 수용액(1→100) 각각 10μL씩을 사용하여 다음의 조작조건으로 액체크로마토그래피법에 따라 시험할 때, 시험용액의 유지시간은 표준용액의 유지시간과 일치하여야 한다. 조작조건 검 출 기 : 시차굴절계(RI Detector) 칼 럼 : Carbohydrate(8mm×300mm) 또는 이와 동등한 것 칼럼온도 : 80℃ 이 동 상 : 물 유 속 : 1mL/min
정량법이 품목을 건조한 다음 약 1g을 정밀히 달아 물에 녹여 100mL로 하고 이 액 10mL를 취하여 이온교환수지[약산성이온교환수지(H형)와 강염기성이온교환수지(OH형)를 용적비로 1 : 4 혼합한 것] 10mL를 충전시킨 칼럼에 유출시킨 후 칼럼을 물로 세정하고 유출액과 세정액을 합하여 염산으로 pH 1.0으로 한 다음 물을 가하여 100mL로 한다. 이 액 5mL를 취한 다음 미리 냉각한 라이네케염시액 5mL를 가해주고 3시간 동안 냉장고에서 냉각시킨다. 이 때 생성된 침전을 유리여과기(3G4)로 여과하고 잔류물을 에테르로 세정한 후 풍건한다. 이 침전물을 70% 아세톤으로 녹여 25mL로 한 것을 시험용액으로 하여 액층 1cm, 파장 525nm에서 흡광도를 측정한다. 별도로 베타인 표준품을 105℃에서 3시간 건조한 후 약 1g을 정밀히 달아 물에 녹여 100mL로 한 것을 표준원액으로 한다. 이 표준원액 10mL 및 20mL를 각각 취한 다음 염산을 가해 pH 1.0으로 하고 물을 가하여 100mL씩으로 한 액을 각각 표준용액으로 한다. 각 표준용액을 5mL씩 취하여 검체와 동일하게 침전조작을 행하여 70% 아세톤으로 녹이고 시험용액과 동일하게 흡광도를 측정하여 검량선을 작성한다. 이 검량선과 시험용액의 흡광도로부터 다음 계산식에 따라 베타인의 함량을 구한다.함 량(%) =검량선에서 구한 검체중의 베타인의 양(%)/ 검체의 채취량(g)×100 시 액라이네케염시액 : 라이네케염 1.5g을 물에 녹이고 염산을 가하여 pH 1.0으로 조정한 후 물을 가하여 100mL로 한다.
정의이 품목은 명아주과 사탕무우(Beta vulgaris L. var. rapa)의 당밀을 분리정제 하여 얻어지는 물질로서 주성분은 베타인(C5H11NO2=117.15)이다.
정의ChEBI: The amino acid betaine derived from glycine.